These findings inspired us to investigate the therapeutic effects of cholesterol lowering drugs from the statin class of the HMG-CoA reductase inhibitors, such as lovastatin, on the in vivo and in vitro growth of ErbB2-positive breast cancers. This evidence concerns the gene HMGCR and breast carcinoma.